Skip to content
Screener

Rigel Pharmaceuticals RIGL Current Debt

Current Debt at other companies

Amgen logo
AmgenAMGN
$5.45B+123%
Opko Health logo
Opko HealthOPK
$912K-40.0%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$11.81M—
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
$0-100%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K—
Free cash flow-$22.0M—

Valuation

See full
Market cap$750.37M+25.0%
Enterprise value$794.27M+44.9%
P/E2.1×-4.1×
P/S2.5×+0.3×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%—

Returns & leverage

See full
Return on equity174.1%—
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths.

The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001034842-26-000032
Remainder of 2026$22,500
202722,500
Principal amount (Tranches 1, 2, 3 and 4)$45,000

Item 1. Financial Statements

FAQ

What is Rigel Pharmaceuticals's current debt?
Rigel Pharmaceuticals (RIGL) reported current debt of $22.5M in Q1 2026.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.

Ask your AI about Rigel Pharmaceuticals's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude